BPDCN is an aggressive type of blood cancer that originates from plasmacytoid dendritic cells (pDCs), a component of the immune system that produces type 1 interferon cytokines. These cytokines ...

Historically, BPDCN treatment relied on chemotherapy regimens adapted from leukemia or lymphoma protocols. However, recent breakthroughs have transformed the treatment paradigm. ELZONRIS (Stemline ...

The FDA called for a clinical hold on the two phase 1 trials of UCART123, in acute myeloid leukaemia, and in blastic plasmacytoid dendritic cell neoplasm (BPDCN). Cellectis said it is working with ...

Privately-held Menarini is paying up to $677 million for Stemline and Elzonris (tagraxofusp-erzs), the biotech’s treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN), which was ...

The interfollicular regions show vascular proliferation and clusters of plasmacytoid dendritic cells ... can evolve into FDC sarcoma. ・ Plasma cell neoplasms: These can appear similar to ...

An expert discusses how, for younger/fitter patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), treatment selection as a bridge to transplant is based on efficacy, toxicity, and ...

Timely transplant referral depends on disease kinetics. Novel therapies are among the unmet needs in plasmacytoid dendritic cell neoplasm. Support resources aid patient management. Emerging treatments ...

Scientists have discovered a new immunotherapy strategy that reduces cancer recurrence in mouse experimental models. The study, published in Nature Communications, shows that a specific subtype of ...